INVITED ABSTRACTS Journal of Thoracic Oncology

INVITED ABSTRACTS Journal of Thoracic Oncology
Journal of Thoracic Oncology Volume 10, Issue 9, Pages S66-S172 (September 2015) DOI: /S (16) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1.1 GLCC Global Lung Cancer E-Atlas home page By clicking on individual countries, or using the search function, users can ‘zoom in’ on different areas to see the figures for that nation. The E-Atlas also has a comparison tool, enabling the user to select up to four countries and directly compare the figures for them (Figure2). Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2.2 the comparator tool GLCC campaigners have been using the E-Atlas to support engagement with national policy-makers and influencers. To support this, the project team produced a campaigning toolkit, giving headline figures, tips for engagement and template materials (press releases, briefing documents and a presentation for adaptation). Conclusions: Feedback from GLCC members confirms that the E-Atlas is a helpful resource in their campaigning and advocacy. The GLCC is continuing to develop the E-Atlas, and it will be updated with breakdowns by age and gender. The GLCC is also keen for the E-Atlas to be shared and to receive feedback (via on additional national data for inclusion or suggestions for further development. References: [i] GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11, Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. Lyon, 2013, France: International Agency for Research on Cancer. Available at: [ii] Global surveillance of cancer survival 1995–2009: analysis of individual data for patients from 279 population-based registries in 67 countries (CONCORD-2), C Allemani, H Weir, H Carreira, R Harewood, D Spika, X Wang, et al. The Lancet, Volume 385, No. 9972, p977–1010, 14 March [iii] EUROCARE-5-a population-based study of cancer survival in Europe by country and age. Available at: [iv] Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data, MP Coleman, D Forman, H Bryan, J Butler, B Rachet, C Maringe, et al. The Lancet Volume 377, No. 9760, p127–138, 8 January [v] Noncommunicable Diseases Country Profiles 2011, World Health Organization (WHO), Available at: Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S66-S172DOI: (10
Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Suggested management of patients with multiple GGOs (courtesy of Jack West Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

SEGMENTECTOMY OF THE ANTERIOR SEGMENT OF THE RIGHT UPPER LOBE (from “Asamura's Operative Thoracic Surgery”) Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 design of the NELSON trial

Figure 1 Percentage of UKLS positive responders (n=75, 958) with an LLP risk of >5%, by individual year of age. The positive response rate increased steadily with higher socioeconomic status: 21.7% of individuals in the lowest (most deprived) IMD quintile gave a positive response compared with 39.7% in the highest quintile (p<0.001;) (Figure 2). The proportion of individuals with a high LLP risk score decreased with higher socioeconomic status; ranging from 18.2% in the most deprived quintile to 8.3% in the least deprived quintile (p<0.001;). LLP risk were offset by, the socio-demographic spectrum of the individuals attending the clinic, which was in proportion to that of the original approached sample. People recruited into the UKLS trial therefore spanned all IMD quintiles in roughly equal numbers, including a representative proportion from more deprived postcodes. However, in the high risk sub group of individuals invited for screening, there was a trend towards individuals of higher socioeconomic status being more likely to consent to participate in the trial. Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Impact of socioeconomic status upon initial response rate (lower line), LLP risk (bars) and trial consent rate (upper line). The demographic and response data from the UKLS pilot trial enable specific recommendations to be made regarding the implementation of any future UK-wide lung LDCT screening programme. Such a programme would need to target those most at risk who may be least likely to take up offers of screening (i.e. the most deprived, current smokers, and the over 70s), and women. Journal of Thoracic Oncology , S66-S172DOI: ( /S (16) ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Adenocarcinoma in situ

Figure 2 Atypical Adenomatous Hyperplasia.

INVITED ABSTRACTS Journal of Thoracic Oncology

Similar presentations

Presentation on theme: "INVITED ABSTRACTS Journal of Thoracic Oncology"— Presentation transcript:

Similar presentations

About project

Feedback

Log in

Auth with social network:

INVITED ABSTRACTS Journal of Thoracic Oncology

Similar presentations

Presentation on theme: "INVITED ABSTRACTS Journal of Thoracic Oncology"— Presentation transcript:

Similar presentations

About project

Feedback